Sampson Lau has over 10 years of experience in the life sciences and financial services sectors.

Sampson currently serves as President of PrimaNova Labs, an integrated MedTech platform developing next generation surgical tools. Previously, Sampson was Director of Investment and Business Development at China Medical System Holdings (“CMS”, HKEX: 0867), responsible for global BD transactions, biotech and medtech equity investments, and managing the company's portfolio of life sciences VC fund investments. Before CMS, Sampson was Vice President at Delos Capital, a Hong Kong based life sciences VC fund specializing in early-stage biotech and medtech investment in the US and China, with responsibilities ranging from sourcing and execution of investment opportunities, to post-investment management and value creation.

In the early years of Sampson's career, he had extensive transaction experience in global M&A and buyout investment, working in investment banking and private equity.

Sampson graduated from the University of Chicago with a Bachelor of Arts in Economics.